Huitai Medical (688617): The vascular intervention platform for electrophysiological devices with thick and thin hair is being improved
Huitai Healthcare (688617): Electrophysiology business is growing rapidly, and domestic and overseas performance continues to improve
Huitai Healthcare (688617): In line with expectations in the second quarter, various businesses progressed steadily
Huitai Medical (688617): The number of electrophysiological surgeries maintained strong growth, and the performance continued to improve
Huitai Healthcare (688617): 2024H1 performance is in line with expectations, and the application for research projects is being approved at an accelerated pace
Huitai Medical (688617): H1's performance is in line with expectations, optimistic about 3D electrophysiology in-hospital promotion and independent brands to accelerate overseas expansion
Huitai Healthcare (688617): Continued high growth performance is in line with expectations
Huitai Healthcare (688617): Profit exceeds our expectations and we are optimistic about long-term growth
Huitai Medical (688617): Rapid growth in 3D surgery volume, smooth expansion of overseas independent brands
Huitai Healthcare (688617): Continued improvement of brand capabilities, steady growth of electrophysiological products
Huitai Healthcare (688617): Performance surpassed expectations and the cardiovascular leader gradually took shape
Huitai Healthcare (688617): Steady operation and accelerated release of profits
Huitai Medical (688617): Electrophysiological surgery volume is growing rapidly, and new vascular intervention products are being released
Tianfeng Securities released a research report on April 8 stating that it maintains Huitai Healthcare's (688617.SH) purchase rating. The main reasons for the rating include: 1) all business segments go hand in hand to help improve future performance; 2) i
Huitai Healthcare (688617): Beautiful performance growth, breakthroughs in all electrophysiological, coronary and peripheral products
Huitai Medical (688617): Rapid growth in 3D surgery volume, accelerated development of the international market
Huitai Healthcare (688617): The performance is in line with expectations, the vascular intervention business is growing strongly, and the international business has performed well
Huitai Healthcare (688617): The 23-year results are in line with expectations, and the net interest rate has increased significantly
Huitai Medical (688617) Annual Report Review: Successful promotion of electrophysiology, strong growth in vascular intervention
Huitai Healthcare (688617): Performance is in line with expectations, strong growth in core business
No Data
No Data